Close Menu

NEW YORK – HalioDx and OSE Immunotherapeutics on Wednesday announced they will conduct a translational investigation to identify potential immune biomarkers for a non-small cell lung cancer treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.